Analysis of cell cycle regulator proteins in non-small cell lung cancer

Journal of Clinical Pathology

Volumn 57, Issue 1, 2004, Pages 58-63

  Esposito, V ^b   Baldi, A ^a,c   Tonini, G ^d   Vincenzi, B ^d   Santini, M ^c   Ambrogi, V ^e   Mineo, T C ^e   Persichetti, P ^d   Liuzzi, G ^f   Montesarchio, V ^b   Wolner, E ^g   Baldi, F ^c   Groeger, A M ^g  

^a D Cotugno Hospital ^*  (Italy)

^b AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^g UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; PROTEIN P16; PROTEIN P21; PROTEIN P53; REGULATOR PROTEIN;

ADULT; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE; CHEMICAL PARAMETERS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 9144243525     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.57.1.58     Document Type: Article

References (28)

1. Jemal A, Chu KC, Tarone RE. Recent trends in lung cancer mortality in the United States. J Natl Cancer Inst 2001;93:277-83.
2. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics. CA Cancer J Clin 2000;50:7-33.
3. Zochbauer-Muller S, Gazdar AF, Minna JD. Molecular pathogenesis of lung cancer. Annu Rev Physiol 2002;64:681-708.
4. Sherr CS. Cancer cell cycles. Science 1996;274:1672-7.
5. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implication in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995;5:127-56.
6. Grana X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors. Oncogene 1995;11:211-19.
7. Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998;16:3158-68.
8. Bravo R, Frank R, Blundell P, et al. Cyclin PCNA is the auxiliary protein of DNA polymerase delta. Nature 1987;326:515-17.
9. Prelich G, Tan C, Kostura M. Functional identity of proliferating cell nuclear antigen and DNA polymerase delta auxiliary protein. Nature 1987;326:517-20.
10. Waga S, Hanno GJ, Beach D, et al. The p21 inhibitor of the cyclin dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-8.
11. Li R, Waga S, Hannon GJ, et al. Differential effects of the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994;371:534-37.
12. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-17.
13. Zirbes TK, Baldus SE, Moenig SP, et al. Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer 2000;89:14-18.
14. Shim YH, Kang GH, Ro JY. Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest 2000;80:689-695.
15. Paradiso A, Rabinovich M, Vallejo C, et al. p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer 1996;69:437-41.
16. Kaplan EL, Meier P. Nonporametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
17. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomised clinical trials requiring prolonged observation of each potient. Br J Cancer 1977;35:1-39.
18. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
19. Caputi M, Esposito V, Baldi A, et al. p53-independent expression of p21 cdk inhibitor in non small cell lung cancer: relationship to survival. Am J Respir Cell Mol Biol 1998;18:213-17.
20. Mitsudomi T, Hamajima N, Ogawa M, et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-63.
21. Shoji T, Tanaka F, Takata T, et al. Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 2002;20:3865-71.
22. Zhou JX, Niehans GA, Shar A, et al. Mechanisms of G1 checkpoint loss in resected early stoge non-small cell lung cancer. Lung Cancer 2001;32:27-38.
23. Kaye FJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer. Oncogene 2002;21:6908-14.
24. Groeger AM, Caputi M, Esposito V, et al. Independent prognostic role of p16 expression in lung cancer. J Thorac Cardiovasc Surg 1999;118:529-35.
25. Franklin DS, Godfrey VL, O'Brien DA, et al. Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 2000;20:6147-58.
26. Mitra J, Dai CY, Somasundaram K, et al. Induction of p21 and inhibition of cdk2 mediated by the tumor suppressor p16. Mol Cell Biol 1999;19:3916-28.
27. Parry D, Mahony D, Wills K, et al. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibition. Mol Cell Biol 1999;19:1775-83.
28. Geradts J, Fong KM, Zimmerman PV, et al. Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 1999;5:791-800.